Articles published by Genmab A/S
< Previous
1
2
Next >
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Announces Changes to its Executive Committee
August 16, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Financial Results for the First Half of 2024
August 08, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Updates 2024 Financial Guidance
August 08, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Takes Full Control of Acasunlimab Development Program
August 05, 2024
From
Genmab A/S
Via
GlobeNewswire
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
June 28, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
June 28, 2024
From
Genmab A/S
Via
GlobeNewswire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
June 26, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 03, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
June 02, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Completes Acquisition of ProfoundBio
May 21, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
Tickers
BNTX
GMAB
Genmab Completes Acquisition of ProfoundBio
May 21, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Financial Results for the First Quarter of 2024
May 02, 2024
From
Genmab A/S
Via
GlobeNewswire
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
PFE
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
April 03, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
April 03, 2024
From
Genmab A/S
Via
GlobeNewswire
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Initiation of Share Buy-Back Program
February 14, 2024
From
Genmab A/S
Via
GlobeNewswire
Genmab Publishes 2023 Annual Report
February 14, 2024
From
Genmab A/S
Via
GlobeNewswire
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
PFE
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
PFE
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
December 09, 2023
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
November 27, 2023
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Major Shareholder Announcement
November 09, 2023
From
Genmab A/S
Via
GlobeNewswire
Major Shareholder Announcement
November 08, 2023
From
Genmab A/S
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.